Express Pharma
Home  »  Latest Updates  »  Acasti Pharma’s krill oil-derived drug fails late-stage study

Acasti Pharma’s krill oil-derived drug fails late-stage study

The Canada-based drug developer said CaPre failed to show a statistically significant reduction in blood triglycerides compared to placebo after 12 weeks and 26 weeks of treatment

0 35
Read Article

Acasti Pharma said its krill oil-derived drug candidate, CaPre, was not more effective than placebo in reducing high levels of triglycerides in a late-stage study.

US-listed shares of Acasti were down 54 per cent at $1 before the bell.

The Canada-based drug developer said CaPre failed to show a statistically significant reduction in blood triglycerides compared to placebo after 12 weeks and 26 weeks of treatment.

Triglycerides are a type of fat found in blood that contributes to heart disease alongside cholesterol.

Leave A Reply

Your email address will not be published.